智通财经网·2025-10-28 09:44Core Viewpoint - Shanghai Pharmaceuticals has received approval from the National Medical Products Administration for the production of Bromidespasm, a sustained-release tablet used to treat myasthenia gravis, marking a significant milestone for the company in expanding its product portfolio [1] Company Summary - Shanghai Pharmaceuticals' subsidiary, Shanghai Shiyou Zhongxi Pharmaceutical Co., Ltd., has been granted a Drug Registration Certificate for Bromidespasm, with the certificate number 2025S03175 [1] - The drug was originally developed by BAUSCH and was first launched in the United States in 1959 [1] - The company submitted the registration application for this drug to the National Medical Products Administration in March 2024, which has been accepted [1] - As of the date of the announcement, the company has invested approximately RMB 16.09 million in research and development for this drug [1]